Product Description
ZSP1603 is an effective anti-fi- brotic compound with clear mechanisms.
Mechanisms of Action: Immunomodulator, PGFRb Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Idiopathic Pulmonary Fibrosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05119972 |
ZSP1603-20-02 | P2 |
Completed |
Idiopathic Pulmonary Fibrosis |
2023-12-21 |
9% |
2025-03-20 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|